Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
J Clin Oncol · 2025-Jan-10 · PMID 39303200
DFS
DFS per BICR in pooled subgroups of interest with sarcomatoid features (A), PD-L1 expression ≥1% (B), or pT4, any grade (N0M0) or any pT, any grade (N1M0) staging (C). Ad hoc analyses were conducted using pooled data from parts A and B of the study to compare DFS per BICR with immunotherapy (nivolumab plus ipilimumab in part A and either nivolumab or nivolumab plus ipilimumab in part B) versus placebo (from parts A and B) in select subgroups of patients. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. PD-L1 testing was performed locally (Labcorp) using a validated tumor proportion score–based PD-L1 immunohistochemical assay (Dako PD-L1 IHC 28-8 pharmDx). BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; NE, not estimable; NR, not reached.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T18:18:52+00:00 |